Today’s news revolves around new revolutionizations in microbiology testing. Spore.Bio has come up with a new technology to apply to microbiology testing in labs. The startup aims to improve testing for efficient working. Spore.Bio has raised $23 Million from investors to implement the technology without hassles.
Spore.Bio in the Market
Spore.Bio is a Paris-based deeptech startup. The company’s target is to reinvent microbiology testing in the testing market landscape. It has gathered $23 million from several reliable investors to use machine learning in testing.
Spore.Bio is a startup that took lessons from the previous contamination incidents in the food and beverage industry. So, the startup is set to introduce new technological machine learning to revolutionize microbiology testing in the required industry.
Spore.Bio $23 million investment is a little more than a year after it raised an $8.3 million pre-seed round. The customer’s interest in the new technology implementation proved beneficial in managing the funds. Spore.Bio is in a deal with up to 200 factories to meet the demands.
The Need to Reinvent Microbiology Testing
Spore.Bio is concerned with the problems with current testing methods used in labs. It comes with new technology and methods that explain the need to reinvent microbiology testing. The traditional testing goes by company sending samples to specialized labs.
There is a risk of potential bacteria when testing samples are on a petri dish, which leads to contamination in other parts of the testing faculty. With current testing methods, procedures take a longer time with risks of contamination.
How Spore.Bio's Technology Works
Anime Raji, founder of Spore.Bio is determined to revolutionize microbiology testing. His deep learning approaches and machine vision to spot dangerous microorganisms. The technology will be beneficial in reducing the timing of testing and preventing the risks of pathogens in the food and beverage industry.
In Spore.Bio technology involves light of specific wavelengths sent toward a sample. These lights record spectral signatures and detect microorganisms in minutes. This way, with the Spore.Bio technology use in labs, the testing time will be minimized from days to minutes. Thus, reducing time delay and avoiding the growth of bacteria.
Spore.Bio’s new technology is its most important asset. The startup has signed a collaboration with the Pasteur Institute to access its bank of bacteria samples.
Spore.Bio Funding and Growth
Spore.Bio has raised $23M in Series A funding. The investors include Singular leading the round, Point 72 Ventures, 1st Kind Ventures (the family office of the Peugeot family), Station F and Lord David Prior. Returning backers LocalGlobe, No Label Ventures and Famille C also invested.
With the funding, the company plans to grow its team from 30 to 50 people by the end of 2025 and develop its technology in the coming future. The startup will soon make testing machines that its customers can incorporate in microbiology testing on-site.
Spore.Bio Demand in Industries
Spore.Bio technology is developed for the food and beverage industry. Many other industries like cosmetic and pharmaceutical companies have shown their interest in the new microbiology testing in technology.